Table 4 (cont.)
______CON |
RSM |
WHO |
RHR |
TRA |
POT |
FIN |
BUS | |
IV model | ||||||||
EXP_entry t+1 |
0.069 |
0.051 |
-0.341 |
-0.605** |
0.122 |
-0.001 |
-0.314 |
-0.260 |
EXP_entry t |
- * |
0.065 |
_ _ _ * -0.376* |
0.104 |
-0.025 |
0.135*** |
0.673*** |
-** |
EXP_entry t-1 |
-0.123 |
0.019 |
-0.157 |
-0.067 |
-0.095 |
0.047 |
0.106 |
-0.160 |
EXP_exit t+1 |
0.069 |
-0.446*** |
-0.426* |
-0.111 |
-0.247* |
0.102** |
-0.267 |
-0.049 |
EXP_exit t |
-0.151 |
0.048 |
0.000 |
-0.596 |
0.033 |
-0.736** |
0.115 |
0.442 |
EXP_exit t-1 |
-0.004 |
0.131* |
-0.375* |
0.111 |
0.087 |
0.359 |
-0.012 |
0.023 |
EXP_both t+1 |
0.033 |
0.166 |
-0.213** |
0.566 |
-0.277 |
0.247 |
0.235 |
-0.434 |
EXP_both t |
0.026 |
0.047 |
0.181 |
0.135 |
-0.291 |
0.109 |
0.542** |
0.025 |
EXP_both t-1 |
-0.010 |
0.078 |
-0.132** |
0.323 |
-0.051 |
0.063 |
0.007 |
-0.284* |
No. of Obs. |
10531 |
6094 |
12753 |
10414 |
3229 |
979 |
15285 |
23841 |
No. of groups |
3055 |
1644 |
3389 |
2978 |
1051 |
337 |
4655 |
7932 |
Control function | ||||||||
EXP_entry t+1 |
0.068 |
* |
-0.291 |
-0.742 |
0.129 |
-0.045 |
-0.682* |
-0.037 |
EXP_entry t |
0.300* |
-0.366 |
_ _ _ *** |
1.253 |
-0.130 |
0.139* |
1.841*** |
1.325** |
EXP_entry t-1 |
0.066 |
0.171** |
-0.158 |
-0.062 |
-0.110 |
-0.155 |
0.025 |
-0.370 |
EXP_exit t+1 |
0.090 |
-0.383** |
-0.314 |
-0.063 |
-0.260* |
*** |
-0.226 |
-0.028 |
EXP_exit t |
-0.549 |
0.588 |
_ _ *** |
-1.794 |
0.319 |
-0.675** |
-0.800 |
-0.243 |
EXP_exit t-1 |
-0.012 |
0.145 |
-0.236 |
0.064 |
0.092 |
0.502 |
-0.032 |
0.092 |
EXP_both t+1 |
0.019 |
0.135 |
-0.239** |
0.784 |
-0.018 |
0.226 |
0.333 |
-0.441 |
EXP_both t |
0.424 |
-0.434 |
_ _ *** |
1.530 |
-0.230 |
1.211 |
___ *** 1.582*** |
0.578 |
EXP_both t-1 |
0.007 |
0.061 |
-0.087 |
0.369 |
0.282 |
-0.154 |
-0.066 |
_ ___*** -0.378*** |
λ1 |
-0.122 |
0.099* |
__*** -0.594*** |
-0.178 |
0.042 |
-0.333* |
-0.183* |
-0.164 |
λ0 |
-1.646 |
-0.289 |
-1.150*** |
-3.512 |
-0.534 |
-0.555 |
-2.217*** |
0.314 |
No. of Obs. |
10531 |
6094 |
12753 |
10414 |
3225 |
979 |
15285 |
23841 |
No. of groups |
3055 |
1644 |
3389 |
2978 |
1050 |
337 |
4655 |
7932 |
Matched sample | ||||||||
EXP_entry t+1 |
0.085* |
0.029 |
-0.342 |
-0.749** |
0.101 |
-0.033 |
-0.228 |
-0.202 |
EXP_entry t |
0.085** |
0.076 |
-0.348* |
0.124 |
0.102 |
0.201** |
0.350*** |
0.303*** |
EXP_entry t-1 |
-0.102** |
0.003 |
-0.146 |
-0.058 |
0.015 |
0.072 |
0.116 |
0.003 |
EXP_exit t+1 |
0.016 |
-0.380*** |
-0.450* |
-0.143 |
-0.195** |
0.080*** |
-0.105 |
0.019 |
EXP_exit t |
-0.142 |
0.000 |
0.025 |
-0.730 |
0.086 |
-0.681*** |
-0.113 |
0.085 |
EXP_exit t-1 |
-0.003 |
0.093 |
-0.340 |
0.107 |
0.056 |
0.446 |
0.019 |
-0.054 |
EXP_both t+1 |
0.030 |
0.063 |
-0.204*** |
0.631 |
-0.386* |
0.156 |
0.064 |
-0.166 |
EXP_both t |
0.027 |
-0.037 |
0.167 |
0.097 |
-0.087 |
0.141 |
0.430** |
0.091 |
EXP_both t-1 |
-0.011 |
-0.038 |
-0.132** |
0.344 |
-0.010 |
0.105 |
0.029 |
-0.168* |
No. of Obs. |
2941 |
1326 |
10688 |
2669 |
1301 |
666 |
3992 |
16164 |
No. of groups_________ |
1338 |
659 |
3118 |
1170 |
623 |
266 |
1807 |
5911 |
Table 4 shows that ‘learning-by-exporting’ is present but it is by no means universal,
and even within industry groups there are differences for entrants, exiting exporters,
and those that experience both entry and exit into overseas markets. To summarise the
29
More intriguing information
1. Segmentación en la era de la globalización: ¿Cómo encontrar un segmento nuevo de mercado?2. Short- and long-term experience in pulmonary vein segmental ostial ablation for paroxysmal atrial fibrillation*
3. Intertemporal Risk Management Decisions of Farmers under Preference, Market, and Policy Dynamics
4. Conditions for learning: partnerships for engaging secondary pupils with contemporary art.
5. A Rare Presentation of Crohn's Disease
6. The Provisions on Geographical Indications in the TRIPS Agreement
7. CAPACITAÇÃO GERENCIAL DE AGRICULTORES FAMILIARES: UMA PROPOSTA METODOLÓGICA DE EXTENSÃO RURAL
8. Peer Reviewed, Open Access, Free
9. An Empirical Analysis of the Curvature Factor of the Term Structure of Interest Rates
10. A novel selective 11b-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis